Abstract:Primary liver cancer (PLC) is the fourth-most common malignancy and second leading cause of tumor-related deaths in China. Hepatocellular carcinoma (HCC) accounts for 75–85% of PLCs. [ 1 ] At present, radical surgery remains the most effective treatment option for HCC, including liver resection and liver transplantation (LT). The indications of LT for HCC are relatively strict because of a shortage of donor livers and the risk of postoperative tumor recurrence and metastasis. Patients with tumor burdens exceeding LT criteria may undergo downstaging treatment to meet the criteria. In recent years, new drugs for HCC have been continuously developed. Among them, systemic therapeutic drugs represented by molecular targeted drugs and immune checkpoint inhibitors (ICIs) have created a new era in the treatment of HCC. [ 2 ] After LT, the main problems for recipients are tumor recurrence and metastasis. Previous studies showed that the 5-year tumor recurrence rate after LT was 20.0–57.8%, and the median survival time of recipients after HCC recurrence was only 12.9 months. [ 3,4 ] Various regional treatments, such as ablation, intervention, and radiation therapy, can be adopted for tumor recurrence and metastasis after LT. Systemic treatment, such as targeted drugs and chemotherapy, is also used in clinical practice. However, there is still some controversies regarding the application of ICIs for preventing or treating tumor recurrence and metastasis. Currently, there is no standardized guidelines or widespread consensus on the application of ICIs in LT for HCC among both domestic and international medical communities. To achieve effective and safe application of ICIs for patients with HCC before and after LT, in August 2023, Organ Transplantation Banch of the Chinese Medical Association convened national experts to jointly formulate the "Chinese expert consensus on the application of immune checkpoint inhibitors in liver transplantation for hepatocellular carcinoma" (full-length version of the consensus can be seen in Supplementary File, https://links.lww.com/CM9/C97 ).

Perioperative diagnosis and treatment strategies of liver transplantation for liver cancer in precision medicine era

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

Prevention and Treatment Strategies of Postoperative Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma

Prevention and Management of Recurrence and Metastasis of Hepatocellular Carcinoma after Liver Transplantation

Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy.

Surgical Treatment of Hepatocellular Carcinoma in the Precision Medicine Era

Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma: Prevention and Treatment

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

Advances in Predicting the Prognosis of Hepatocellular Carcinoma Recipients after Liver Transplantation

Precise Hepatectomy In The Intelligent Digital Era

Liver Transplantation for Liver Cancer in the Era of Immunotherapy

Precision Diagnosis and Treatment of Liver Cancer in China.

Transplant oncology and stratified management of hepatocellular carcinoma

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation

Progress in hepatectomy for hepatocellular carcinoma and peri-operation management

Progress and hot spots of comprehensive treatment for primary liver cancer

Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients

Chinese expert consensus on the application of immune checkpoint inhibitors in liver transplantation for hepatocellular carcinoma

The impact of biological features for a better prediction of posttransplant hepatocellular cancer recurrence

[Prediction and Preventive Strategies for Recurrence after Surgery for Hepatocellular Carcinoma].